The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study
Dermatology Research and Practice · 18.04.2019 · 2019 · 1-9
DOI: 10.1155/2019/5237642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Research and Practice, erschienen am 18.04.2019. Verfasst von Wareeporn Disphanurat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thammasat University Research Fund.
Abstract (Originalsprache)
Background
There are limited randomized controlled trials of oral vitamin D supplementation in psoriasis, especially in Asia, and the results are inconclusive.
Objective
To investigate the clinical effect of oral vitamin D supplementation on psoriasis.
Methods
Patients with psoriasis were randomized to receive vitamin D2 60,000 IU or similar-looking placebo pills once every 2 weeks for 6 months. The primary outcome was improvement of the Psoriasis Area and Severity Index (PASI) score at 3 and 6 months after treatment. Serum levels of 25(OH)D, calcium, phosphate, parathyroid hormone, and C-reactive protein and adverse events were monitored. The chi-square test, Fisher’s exact test, Student’s t-test, and Spearman’s correlation analysis were used in statistical analysis.
Results
Of 50 subjects screened, 45 were eligible and randomized to the oral vitamin D2 group (n=23) or placebo group (n=22). At enrollment, the mean PASI score was 4.45, and 26.7% of patients had vitamin D deficiency. At 3 months, the oral vitamin D2 group had significantly higher PASI improvement than the placebo group (mean PASI improvement: 1.43 versus [vs.] -0.33, p-value=0.034; mean %PASI improvement: 34.21% vs. -1.85%, p-value=0.039). The mean serum 25(OH)D level was significantly higher in the oral vitamin D group than in the placebo group (27.4 vs. 22.4 ng/mL, p-value=0.029). Serum 25(OH)D concentrations were significantly inversely correlated with PASI scores at the 6-month follow-up. No major adverse event was observed overall.
Conclusion
Oral vitamin D2 supplementation in patients with psoriasis increased the serum vitamin D level and significantly improved the treatment outcome without increasing adverse events. Trial Registration. This trial is registered with Thai Clinical Trials Registry TCTR20180613001 .
Autor:innen und Institutionen
- Dermatology Unit, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand.
ORCID-Profile: Wareeporn Disphanurat
Förderung
- Thammasat University Research Fund
Zitieren
APA
Disphanurat, W., Viarasilpa, W., Chakkavittumrong, P., & Pongcharoen, P. (2019). The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study. Dermatology Research and Practice, 2019, 1-9. https://doi.org/10.1155/2019/5237642
Vancouver
Disphanurat W, Viarasilpa W, Chakkavittumrong P, Pongcharoen P. The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study. Dermatology Research and Practice. 2019;2019:1-9. doi:10.1155/2019/5237642
BibTeX
@article{Disphanurat2019,
author = {Disphanurat, Wareeporn and Viarasilpa, Wongsiya and Chakkavittumrong, Panlop and Pongcharoen, Padcha},
title = {The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study},
journal = {Dermatology Research and Practice},
year = {2019},
volume = {2019},
pages = {1--9},
doi = {10.1155/2019/5237642}
}
EUVIMED